Legend Biotech dual-target CAR-T shows early efficacy in lymphoma
Legend Biotech (NASDAQ:LEGN) announced encouraging initial clinical data from an ongoing Phase 1 study evaluating LB2501, its experimental in vivo CD19/CD20 dual-targeting CAR-T therapy, for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.







_1412509_640x360_2502174275918-640x360.webp&w=3840&q=75)

_1412502_640x360_2502174275638-640x360.webp&w=3840&q=75)
_1412498_640x360_2502171715885-640x360.webp&w=3840&q=75)
